(ANSA) - BRUSSELS, APRIL 20 - The European Medicines Agency (Ema) recognizes "possible" cause-and-effect links between the Johnson & Johnson vaccine and the "very rare" cerebral thrombosis events that occurred in the US.
This was stated in a note by Ema herself at the end of the serum review, after very rare cases of cerebral thrombosis in the United States, specifying however that "the benefits outweigh the risks".
"The cases of rare events examined after the J & J vaccine are very similar to the cases that occurred with the Covid-19 vaccine developed by AstraZeneca", emphasizes the European Medicines Agency, specifying that all rare events of cerebral thrombosis "have occurred in people of less than 60 years of age within three weeks of vaccination "with Johnson & Johnson serum," the majority in women. Based on the evidence currently available - it is added -, the specific risk factors have not been confirmed.
"The safety committee of the European Medicines Agency concluded that a warning about unusual blood clots with low platelets should be added to the information" in the leaflet "about the product for the Janssen vaccine," by Johnson & Johnson, "the release clarifies. - the events should be listed as very rare side effects of the vaccine ". (HANDLE).